Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Max W. Sung, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Masatoshi Kudo, Ryosuke Tateishi, Masafumi Ikeda, Valery Breder, Kun-Ming Rau, Yuk Ting Ma, Angel Alsina, Baek-Yeol Ryoo, Zhenggang Ren, Kalgi Mody, Corina E. Dutcus, Toshiyuki Tamai, Kenichi Saito, Fabio Piscaglia
Institutions: Tisch Cancer Institute, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, 81th Hospital of PLA, Yonsei University, Severance Hospital, Toranomon Hospital, National Taiwan University Hospital, Kindai University, University of Tokyo Hospital, National Cancer Center Hospital East, Russian Cancer Research Center NN Blokhin, E-Da Hospital, Queen Elizabeth Hospital Birmingham, Tampa General Hospital, Asan Medical Center, University of Ulsan, Fudan University, Zhongshan Hospital, Eisai (United States), Eisai (Japan), University of Bologna
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2914940499